PH12020550239A1 - Periodontitis vaccine and related compositions and methods of use - Google Patents

Periodontitis vaccine and related compositions and methods of use

Info

Publication number
PH12020550239A1
PH12020550239A1 PH12020550239A PH12020550239A PH12020550239A1 PH 12020550239 A1 PH12020550239 A1 PH 12020550239A1 PH 12020550239 A PH12020550239 A PH 12020550239A PH 12020550239 A PH12020550239 A PH 12020550239A PH 12020550239 A1 PH12020550239 A1 PH 12020550239A1
Authority
PH
Philippines
Prior art keywords
antigen sequence
rgpa
sequence
gingipain
methods
Prior art date
Application number
PH12020550239A
Other languages
English (en)
Inventor
Jeffery Fairman
Original Assignee
Vaxcyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxcyte Inc filed Critical Vaxcyte Inc
Publication of PH12020550239A1 publication Critical patent/PH12020550239A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PH12020550239A 2017-10-12 2020-04-08 Periodontitis vaccine and related compositions and methods of use PH12020550239A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762571582P 2017-10-12 2017-10-12
PCT/US2018/055496 WO2019075260A1 (en) 2017-10-12 2018-10-11 VACCINE AGAINST PERIODONTITIS AND ASSOCIATED COMPOSITIONS AND METHOD OF USE

Publications (1)

Publication Number Publication Date
PH12020550239A1 true PH12020550239A1 (en) 2021-02-15

Family

ID=64110091

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020550239A PH12020550239A1 (en) 2017-10-12 2020-04-08 Periodontitis vaccine and related compositions and methods of use

Country Status (14)

Country Link
US (3) US10835590B2 (enExample)
EP (1) EP3694547A1 (enExample)
JP (2) JP7258870B2 (enExample)
KR (2) KR102530966B1 (enExample)
CN (1) CN111225684A (enExample)
AU (1) AU2018347511A1 (enExample)
CA (1) CA3078630A1 (enExample)
EA (1) EA202090908A1 (enExample)
IL (1) IL273690A (enExample)
MA (1) MA50363A (enExample)
MX (1) MX2020003810A (enExample)
PH (1) PH12020550239A1 (enExample)
SG (1) SG11202003147XA (enExample)
WO (1) WO2019075260A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111225684A (zh) 2017-10-12 2020-06-02 Sutrovax公司 牙周炎疫苗和相关组合物及使用方法
US12637503B2 (en) 2020-11-03 2026-05-26 K-Bio Investment, Llc Antigen-binding molecules that bind to Porphyromonas gingivalis
WO2025019900A1 (en) * 2023-07-26 2025-01-30 Denteric Pty Ltd Chimeric protein vaccine
CN116751292B (zh) * 2023-07-31 2024-05-14 河南大学 牙龈卟啉单胞菌Mfa1单克隆抗体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59128338A (ja) 1982-12-08 1984-07-24 Kitasato Inst:The 歯周炎予防用ワクチン及びその製法
WO1994028014A2 (en) 1993-05-28 1994-12-08 Chiron Corporation Peptide inhibitors of urokinase receptor activity
AUPN627595A0 (en) * 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
JP2000507245A (ja) 1996-03-22 2000-06-13 ユニバーシティー オブ ジョージア リサーチ ファウンデーション,インコーポレイテッド Porphyromonas gingivalisペプチドを含む免疫原性組成物および方法
US6833262B1 (en) 1999-04-21 2004-12-21 University Of Georgia Research Foundation, Inc. Polypeptide having amidolytic activity for a serpin
AUPQ065299A0 (en) 1999-05-28 1999-06-24 University Of Sydney, The A method of prophylaxis and treatment and agents useful for same
AUPQ485999A0 (en) * 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
US7378101B2 (en) 2001-12-21 2008-05-27 Pfizer, Inc. Vaccine for periodontal disease
GB0411150D0 (en) 2004-05-19 2004-06-23 Queen Mary & Westfield College Vaccine
MX2012001495A (es) 2009-08-02 2012-08-03 Sanofi Pasteur Ltd Polipeptidos de porphyromonas gingivalis.
AU2011214908A1 (en) 2010-02-12 2012-09-20 Sydney West Area Health Services (Swahs) Protein domains and uses therefor
WO2011130544A2 (en) 2010-04-14 2011-10-20 Sutro Biopharma, Inc. Monitoring a dynamic system by liquid chromatography-mass spectrometry
WO2014058830A1 (en) 2012-10-12 2014-04-17 Sutro Biopharma, Inc. Proteolytic inactivation of select proteins in bacterial extracts for improved expression
EP3365027B1 (en) * 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
CN111225684A (zh) 2017-10-12 2020-06-02 Sutrovax公司 牙周炎疫苗和相关组合物及使用方法

Also Published As

Publication number Publication date
US11701414B2 (en) 2023-07-18
CA3078630A1 (en) 2019-04-18
WO2019075260A1 (en) 2019-04-18
EA202090908A1 (ru) 2020-10-29
IL273690A (en) 2020-05-31
US20190192645A1 (en) 2019-06-27
JP2020536925A (ja) 2020-12-17
US20240131134A1 (en) 2024-04-25
US20210361756A1 (en) 2021-11-25
JP7258870B2 (ja) 2023-04-17
KR102530966B1 (ko) 2023-05-15
KR20230066660A (ko) 2023-05-16
MA50363A (fr) 2020-08-19
AU2018347511A1 (en) 2020-05-21
EP3694547A1 (en) 2020-08-19
US10835590B2 (en) 2020-11-17
KR20200070302A (ko) 2020-06-17
AU2018347511A8 (en) 2020-06-11
CN111225684A (zh) 2020-06-02
BR112020006500A2 (pt) 2020-10-13
US20240226259A9 (en) 2024-07-11
SG11202003147XA (en) 2020-05-28
JP2023098935A (ja) 2023-07-11
US12121575B2 (en) 2024-10-22
MX2020003810A (es) 2020-08-13

Similar Documents

Publication Publication Date Title
CY1119436T1 (el) Σκευασμα για αντισωμα εναντι- 4 7
BR112022005687A2 (pt) Vacinas contra o hbv e métodos para tratar o hbv
MX2020003810A (es) Vacuna contra la periodontitis y composiciones relacionadas y metodos de uso.
MX357505B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2018014631A (es) Formulacion de neurotoxina.
EA201692315A1 (ru) Составы и способы обработки кератина
CL2018003178A1 (es) Composición farmacéutica
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MA40151A1 (fr) Vaccins de recombinaison fmdv et leurs utilisations
ECSP088159A (es) Formulaciones de inmunoconjugado
AR081809A1 (es) Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
EA201991065A1 (ru) Вакцина против свиного парвовируса
EA202091318A1 (ru) Препарат, содержащий аденовирус группы b
MX2021008035A (es) Inmunógenos peptídicos dirigidos al péptido relacionado con el gen de la calcitonina (cgrp) y sus formulaciones para la prevención y el tratamiento de la migraña.
ZA202102816B (en) High concentration protein formulation
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
MX2023009447A (es) Anticuerpos que se unen a metapneumovirus, proteínas antigénicas de metapneumovirus, y usos de los mismos.
EA202091563A1 (ru) Человеческие антитела к гемагглютинину вируса гриппа
JP2020536925A5 (enExample)
MX2022009549A (es) Tratamiento que implica vacunacion con antigeno y agentes de union que se unen a pd-l1 y cd137.
MX2021011913A (es) Composiciones de virus inactivado y formulaciones de vacunas contra el zika.
MX2025013140A (es) Composiciones para el uso en el tratamiento del acne
PE20201166A1 (es) Metodos y composiciones para tratar enfermedades pulmonares cronicas
WO2013171661A3 (en) Adjuvant formulations and methods
MX2024005962A (es) Composiciones de proteínas de fusión inmunogénicas y métodos de uso de estas